Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an update.
Shanghai Henlius Biotech, Inc. announced that the U.S. FDA has approved the investigational new drug application for HLX17, a biosimilar of pembrolizumab, for phase 1 clinical trials. This approval marks a significant step for the company as it aims to conduct international multi-center trials, potentially enhancing its position in the oncology market, where pembrolizumab sales reached approximately USD 32.056 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biosimilar drugs. The company specializes in creating recombinant humanized monoclonal antibodies for various cancer treatments, targeting a global market with significant demand for innovative oncology solutions.
Average Trading Volume: 1,403,180
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.49B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.